Effects on skin dose from unwanted air gaps under bolus in an MR-guided linear accelerator (MR-linac) system.

Bolus is commonly used in MV photon radiotherapy to increase superficial dose and improve dose uniformity for treating shallow lesions. However, irregular patient body contours can cause unwanted air gaps between a bolus and patient skin. The resulting dosimetric errors could be exacerbated in MR-Linac treatments, as secondary electrons generated by photons are affected by the magnetic field. This study aimed to quantify the dosimetric effect of unwanted gaps between bolus and skin surface in an MR-Linac. A parallel-plate ionization chamber and EBT3 films were utilized to evaluate the surface dose under bolus with various gantry angles, field sizes, and different air gaps. The results of surface dose measurements were then compared to Monaco 5.40 Treatment Planning System (TPS) calculations. The suitability of using a parallel-plate chamber in MR-Linac measurement was validated by benchmarking the percentage depth dose and output factors with the microDiamond detector and air-filled ionization chamber measurements in water. A non-symmetric response of the parallel-plate chamber to oblique beams in the magnetic field was characterized. Unwanted air gaps significantly reduced the skin dose. For a frontal beam, skin dose was halved when there was a 5 mm gap, a much larger difference than in a conventional linac. Skin dose manifested a non-symmetric pattern in terms of gantry angle and gap size. The TPS overestimated skin dose in general, but shared the same trend with measurement when there was no air gap, or the gap size was larger than 5 mm. However, the calculated and measured results had a large discrepancy when the bolus-skin gap was below 5 mm. When treating superficial lesions, unwanted air gaps under the bolus will compromise the dosimetric goals. Our results highlight the importance of avoiding air gaps between bolus and skin when treating superficial lesions using an MR-Linac system.

Combination Therapy of Pulsed-Wave Ultrasound Hyperthermia and Immunostimulant OK-432 Enhances Systemic Antitumor Immunity for Cancer Treatment.

PURPOSE: In this study, we hypothesized that systemic antitumor immunity might be enhanced by combining pulsed-wave ultrasound hyperthermia (pUSHT) with OK-432 and that the induced antitumor immunity could confer protection against tumorigenesis. These hypotheses were tested in bilateral and rechallenged tumor models. METHODS AND MATERIALS: Bilateral and rechallenged tumor models were applied in the studies. In the bilateral tumor model, BALB/c mice were inoculated in both flanks with CT26-luc tumor cells. The tumors in the right flank were treated with 4 courses of pUSHT with or without OK-432. In the rechallenged tumor model, tumor cells were implanted into the right flank. Once formed, the tumors were treated with pUSHT with OK-432, followed by surgical resection. New tumor cells were then implanted into the contralateral flank. The antitumor response was evaluated via infiltrated immune cells and the severity of necrosis/apoptosis in tumors. RESULTS: In the bilateral tumor model, the tumor growth rate and growth activity of both treated (100% reduction) and untreated tumors (90.5% reduction) were significantly inhibited with the combination treatment compared with the sham control group, and the systemic antitumor effect was prolonged. The survival rate was significantly enhanced (sham control, 8 days; OK plus pUSHT, >20 days). IFNγ+ CD4 (treated tumor, 8.6-fold; untreated tumor, 4-fold), IFNγ+ CD8 (treated tumor, 6.7-fold; untreated tumor, 2.6-fold), and T cell and NK cell (treated tumor, 4-fold; untreated tumor, 2.5-fold) infiltration was increased in the combination group compared with the control group. In the rechallenged tumor model, new tumors failed to form with the combination treatment. CONCLUSION: This experimental study combining pUSHT and OK-432 explored a new therapeutic strategy for controlling colon cancer metastasis. The results show that the combination treatment may produce an effective antitumor immune response.